EXACT Sciences Corporation

420 articles with EXACT Sciences Corporation

• Exact Sciences Selects Veeva Vault Clinical Suite to Help Accelerate Innovation

  10/14/2020

  Veeva Systems announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies.

• Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer

  10/12/2020

  Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or  recurrent cancer. The Oncotype

• Exact Sciences schedules third quarter 2020 earnings call

  10/9/2020

  Exact Sciences Corp. announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020.

• Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement

  10/7/2020

  Exact Sciences Corp. and Pfizer Inc. announced an extension and amendment of their agreement to promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer.

• Exact Sciences to participate in Cowen Liquid Biopsy Summit

  9/17/2020

  Exact Sciences Corp. announced that company management will participate in the following event and invited investors to participate by webcast.

• Exact Sciences to participate in September investor conference - Sep 01, 2020

  9/1/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences to participate in August 2020 investor conference

  8/3/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences schedules annual meeting, second quarter 2020 earnings call

  7/8/2020

  Exact Sciences Corp. announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020 earnings call.

• Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

  6/16/2020

  Findings, published in Urology, suggest that GPS™ results can help guide the intensity of clinical management in this higher-risk patient population

• Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

  5/29/2020

  - New data and society guidelines support value of Oncotype DX Breast Recurrence Score® test in guiding neoadjuvant treatment decisions for newly diagnosed patients - Mayo Clinic collaboration yielding new data and insights on some of the deadliest cancers

• Exact Sciences to participate in June 2020 investor conferences

  5/26/2020

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

  5/14/2020

  Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test's impact on clinical practice with chemotherapy-sparing effect

• Exact Sciences Announces First Quarter 2020 Results

  5/6/2020

  Exact Sciences Corp. announced that the company generated revenue of $347.8 million for the first quarter ended Mar. 31, 2020, compared to $162.0 million for the same period of 2019.

• Exact Sciences to participate in May 2020 investor conference

  5/4/2020

  Exact Sciences Corp. announced that company management will participate in the following investor conference and invited investors to participate by webcast..

• Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth

  4/2/2020

  Exact Sciences Corp. announced it would be devoting significant patient education resources toward the ability to request Cologuard® online through a telehealth provider.

• Exact Sciences Takes Action during COVID-19 Pandemic

  3/19/2020

  Exact Sciences Corp. provided an update on the actions it is taking to support patients, employees, and public health initiatives in response to the coronavirus pandemic.

• Exact Sciences Extends Leadership In Advanced Cancer Diagnostics With Acquisitions Of Paradigm And Viomics

  3/3/2020

  Exact Sciences Corp. announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two privately held companies based in Phoenix.

• Exact Sciences to participate in March 2020 investor conferences

  2/26/2020

  Exact Sciences Corp. announced that company management will participate in the following investor conferences and invited investors to participate by webcast.

• Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2028

  2/25/2020

  Exact Sciences Corporation announced that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2028 and upsized the offering from $850 million to $1.0 billion aggregate principal amount.

• Exact Sciences Announces Offering of $850 Million Convertible Senior Notes Due 2028

  2/24/2020

  Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $850 million aggregate principal amount of convertible senior notes due 2028 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3.